由KRAS G12V和一种新型TIG3形成的复合物的结构洞察力
Min Seon Ha1, Chang Woo Han2, Mi Suk Jeong2
1Department of Molecular Biology, College of Natural Sciences, Pusan National University, 2, Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan 46241, Republic of Korea.
研究人员从TIG3蛋白中开发了一种新,该向胰腺癌中KRAS G12V突变. 这种具有作为KRAS抑制剂的潜力,为胰腺管道腺癌提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 结构生物学 结构生物学
背景情况:
- 胰腺癌的预后很差,KRAS突变是常见的和关键的治疗点.
- 在开发有效的抗癌药物方面,KRAS蛋白质的结构带来了重大挑战.
- 像TIG3这样的II型瘤抑制剂正在探索新的治疗策略.
研究的目的:
- 开发和描述一种针对KRAS G12V突变的新型抑制剂.
- 调查对KRAS G12V的结合机制和结构影响.
- 评估TIG3衍生在KRAS G12V突变癌细胞中的治疗潜力.
主要方法:
- 从TIG3蛋白质中开发.
- 结合亲和度测试以确认与KRAS G12V的相互作用.
- 进行X射线晶体学以确定-KRAS G12V复合物的结构.
- 在携带KRAS G12V的癌细胞系上进行细胞活力测试.
主要成果:
- 一种来自TIG3的新表明了对KRAS G12V的中等亲和力结合.
- X射线结晶学揭示了Switch II域附近的结合,诱导了KRAS G12V的结构变化.
- 该显著降低了具有KRAS G12V突变的癌症细胞系的活力.
结论:
- 这种新型的TIG3衍生是KRAS G12V向癌症治疗的有希望的候选者.
- 这项研究为开发治疗胰腺管道腺癌的治疗方法提供了关键的结构性见解.
- 这种代表了针对KRAS驱动的恶性瘤的潜在新策略.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
07:08Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
相关概念视频
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
TGF - β Signaling Pathway
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
